China Drug Evaluation Report 2020-Reform of Drug Review & Approval System

by Heng Du
Aug 27, 2021

On June 21, 2021, the National Medical Products Administration (NMPA), to which the Center for Drug Evaluation (CDE) is affiliated, issued the China Drug Evaluation Report 2020.1 

This article collects key information from the report to inform global pharmaceutical companies of the drug approvals in China last year and the approval tendency in the past few years.

Part 1China Drug Evaluation Report 2020-Critical Numbers

Part 2China Drug Evaluation Report 2020-Disapproval Reasons

The following passage is Part 3 of the article.

6. Advancing the Reform of Drug Review & Approval System

6.1 Expediting the Review of Overseas New Drugs in Urgent Clinical Needs

Based on the comments from the expert team and the public, CDE has selected a total of 74 overseas new drugs urgently needed in China's clinical settings. The drugs will enjoy China's policy support, such as expedited programs for marketing authorization.

You can access to the English information of the overseas drugs urgently needed in China in BaiPharm Database.

6.2 Accelerating Consistency Evaluation of Generic Drugs

Heng Du
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact